Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Adrienne Duncan

Physician Assistant, Medical Rockville, MD Physician Assistant

NPI 1902086572 CMS profile 10661598

9901 Medical Center Dr, Rockville, MD 20850

Open in the dashboard

General payments

$9,362

483 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adrienne Duncan of Rockville, MD is reported in the CMS Open Payments database as having received $9,362 across 483 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,422 176
2024 General $3,281 165
2023 General $2,442 129
2022 General $216 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adrienne Duncan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Adrienne Duncan were reported at $3,422. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Adrienne Duncan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $216 $185 $55–$649 $149
2023 $2,442 $199 $58–$717 $160
2024 $3,281 $206 $62–$740 $164
2025 $3,422 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $2,159 105 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $905 62 payments
  3. Pfizer Inc. $717 40 payments
  4. Ardelyx, Inc. $699 40 payments
  5. Janssen Biotech, Inc. $589 26 payments
  6. QOL Medical, LLC $572 28 payments
  7. Gilead Sciences, Inc. $560 20 payments
  8. Madrigal Pharmaceuticals $440 12 payments
  9. Celgene Corporation $418 35 payments
  10. Intercept Pharmaceuticals, Inc. $336 13 payments
  11. Other $1,966 102 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $9,205 475 payments
  2. Education $156 8 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $930 55 payments
  2. XIFAXAN $800 48 payments
  3. LINZESS $714 33 payments
  4. IBSRELA $699 40 payments
  5. CREON $661 30 payments
  6. SKYRIZI Immunology $618 31 payments
  7. VELSIPITY $568 33 payments
  8. SKYRIZI Immunology $542 34 payments
  9. XELJANZ $508 29 payments
  10. Sucraid $481 22 payments
  11. Other $4,907 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

264

Median for Physician Assistant: 241

Drug cost

$239,536

Median for Physician Assistant: $4,110

Branded share of claims

25.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 14 $107,387
Creon Lipase/Protease/Amylase Brand 19 $58,521
Ibsrela Tenapanor Hcl Brand 17 $29,800
Linzess Linaclotide Brand 17 $24,163
Mesalamine Generic 11 $8,952
Sucralfate Generic 22 $6,875
Esomeprazole Magnesium Generic 32 $1,862
Famotidine Generic 49 $883
Omeprazole Generic 42 $572
Pantoprazole Sodium Generic 30 $419

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $453
$453 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $330
$330 — —
SKYRIZI
  • AbbVie, Inc. $313
$313 — —
IBSRELA
  • Ardelyx, Inc. $228
$228 17 —
RINVOQ
  • AbbVie, Inc. $215
$215 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

483 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record